These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 1243126

  • 1. A new central direct dopaminergic stimulant: 1-(Coumaran-5-yl methyl)-4-(2-thiazolyl) piperazine hydrochloride (S 3608).
    Poignant JC, Gressier H, Petitjean M, Regnier G, Canevari R.
    Experientia; 1975 Oct 15; 31(10):1204-5. PubMed ID: 1243126
    [No Abstract] [Full Text] [Related]

  • 2. Evidence that nigral GABA mediates behavioural responses elicited by striatal dopamine receptor stimulation.
    Di Chiara G, Morelli M, Porceddu ML, Gessa GL.
    Life Sci; 1978 Nov 13; 23(20):2045-51. PubMed ID: 569236
    [No Abstract] [Full Text] [Related]

  • 3. Apomorphine and amphetamine stereotypy after 6-hydroxydopamine lesions of the substantia nigra.
    Price MT, Fibiger HC.
    Eur J Pharmacol; 1974 Dec 13; 29(2):249-52. PubMed ID: 4613562
    [No Abstract] [Full Text] [Related]

  • 4. Effects of chronic morphine treatment on dopamine-mediated turning behaviour in rats and mice with 6-hydroxydopamine-induced unilateral nigro-striatal lesions.
    Slater P, Crossman AR.
    Neuropharmacology; 1980 Mar 13; 19(3):289-95. PubMed ID: 7191487
    [No Abstract] [Full Text] [Related]

  • 5. Proceedings: Differences in circling responses following electrolytic and 6-hydroxydopamine lesions of the nigro-striatal pathway.
    Costall B, Marsden CD, Naylor RJ, Pycock CJ.
    Br J Pharmacol; 1975 Oct 13; 55(2):289P-290P. PubMed ID: 1238135
    [No Abstract] [Full Text] [Related]

  • 6. Evidence for a role of endogenous opioids in the nigrostriatal system: influence of naloxone and morphine on nigrostriatal dopaminergic supersensitivity.
    Hirschhorn ID, Hittner D, Gardner EL, Cubells J, Makman MH.
    Brain Res; 1983 Jun 27; 270(1):109-17. PubMed ID: 6409355
    [Abstract] [Full Text] [Related]

  • 7. Blockade of lergotrile or apomorphine induced turning behavior by haloperidol and clozapine.
    Nakamura S, Engel J, Goldstein M.
    Commun Psychopharmacol; 1978 Jun 27; 2(3):185-90. PubMed ID: 29742
    [No Abstract] [Full Text] [Related]

  • 8. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.
    Johnson AM, Loew DM, Vigouret JM.
    Br J Pharmacol; 1976 Jan 27; 56(1):59-68. PubMed ID: 943193
    [Abstract] [Full Text] [Related]

  • 9. Dopaminergic effects of lergotrile: possible involvement of a metabolite.
    McDevitt JT, Setler PE.
    Neuropharmacology; 1980 Jun 27; 19(6):537-42. PubMed ID: 6105627
    [No Abstract] [Full Text] [Related]

  • 10. Ergot alkaloids. New ergolines as selective dopaminergic stimulants.
    Stütz PL, Stadler PA, Vigouret JM, Jaton A.
    J Med Chem; 1978 Aug 27; 21(8):754-7. PubMed ID: 567695
    [Abstract] [Full Text] [Related]

  • 11. Behavioural sequelae of dopaminergic degeneration: postsynaptic supersensitivity?
    Creese I, Iversen SD.
    Psychopharmacol Bull; 1975 Oct 27; 11(4):12-3. PubMed ID: 1197588
    [No Abstract] [Full Text] [Related]

  • 12. Dopamine antagonist binding increases in two behaviorally distinct striatal denervation syndromes.
    Thal L, Mishra RK, Gardner EL, Horowitz SG, Varmuza S, Makman MH.
    Brain Res; 1979 Jul 13; 170(2):381-6. PubMed ID: 572733
    [No Abstract] [Full Text] [Related]

  • 13. Potentiation of apomorphine-induced rotational behaviour by naloxone.
    Quock RM, Welsh TB.
    J Pharm Pharmacol; 1981 Feb 13; 33(2):111-3. PubMed ID: 6111591
    [No Abstract] [Full Text] [Related]

  • 14. Behavioral correlates of dopaminergic supersensitivity.
    Iversen SD, Creese I.
    Adv Neurol; 1975 Feb 13; 9():81-92. PubMed ID: 1170717
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Benzamide potentiation of behavioral apomorphine-induced effects; mechanism involved.
    Piriou F, Petit JY, Welin L.
    Experientia; 1985 Nov 15; 41(11):1409-10. PubMed ID: 2998860
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.
    Wolfarth S.
    Pol J Pharmacol Pharm; 1976 Nov 15; 28(5):469-93. PubMed ID: 796834
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.